Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 23946779)


Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model.

Zhang XH, Qiao EQ, Gao Z, Yuan HQ, Cai PF, Li XM, Gu YH.

Oncol Lett. 2013 Jul;6(1):69-74. Epub 2013 May 14.


Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.

Zhang X, Fang X, Gao Z, Chen W, Tao F, Cai P, Yuan H, Shu Y, Xu Q, Sun Y, Gu Y.

Anticancer Drugs. 2014 Feb;25(2):204-11. doi: 10.1097/CAD.0000000000000033.


Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.

Thallinger C, Werzowa J, Poeppl W, Kovar FM, Pratscher B, Valent P, Quehenberger P, Joukhadar C.

J Invest Dermatol. 2007 Oct;127(10):2411-7. Epub 2007 May 17.


Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.

Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652.


Orally administered rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice.

Thallinger C, Skorjanec S, Soleiman A, Tzaneva S, Griss J, Rous W, Poeppl W, Weinlich G, Karimian-Teherani D, Joukhadar C.

Pharmacology. 2008;82(3):233-8. doi: 10.1159/000156490. Epub 2008 Sep 23.


Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.

Canu B, Fioravanti A, Orlandi P, Di Desidero T, Alì G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R, Bocci G.

Neoplasia. 2011 Mar;13(3):217-29.


Efficacy of dacarbazine (DTIC) in preventing metastases arising from intraocular melanomas in mice.

Sanborn GE, Niederkorn JY, Gamel JW.

Graefes Arch Clin Exp Ophthalmol. 1992;230(2):192-6.


Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

Serrone L, Zeuli M, Sega FM, Cognetti F.

J Exp Clin Cancer Res. 2000 Mar;19(1):21-34.


Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O.

Clin Cancer Res. 2011 Dec 1;17(23):7462-9. doi: 10.1158/1078-0432.CCR-11-0534. Epub 2011 Oct 5.


[Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft].

Zhao J, Zhao T, Xie F, He B.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Jun;32(6):890-3. Chinese.


Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.

Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O.

J Gene Med. 2007 Jun;9(6):440-51.


Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.

Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F; Thymosin Melanoma Investigation Group.

J Clin Oncol. 2010 Apr 1;28(10):1780-7. doi: 10.1200/JCO.2009.25.5208. Epub 2010 Mar 1.


The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.

Rössler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A, Vassal G, Geoerger B.

Int J Cancer. 2011 Jun 1;128(11):2748-58. doi: 10.1002/ijc.25611. Epub 2010 Oct 8.


Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.

Valero T, Steele S, Neumüller K, Bracher A, Niederleithner H, Pehamberger H, Petzelbauer P, Loewe R.

J Invest Dermatol. 2010 Apr;130(4):1087-94. doi: 10.1038/jid.2009.368. Epub 2009 Nov 26.


Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.

Heere-Ress E, Boehm J, Thallinger C, Hoeller C, Wacheck V, Birner P, Wolff K, Pehamberger H, Jansen B.

J Invest Dermatol. 2005 Aug;125(2):201-6. Erratum in: J Invest Dermatol. 2005 Dec;125(6):1320.


Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G.

J Invest Dermatol. 2013 Feb;133(2):499-508. doi: 10.1038/jid.2012.273. Epub 2012 Sep 6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk